Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer

Panavance Therapeutics, Inc. announced the US FDA has granted Orphan Drug Designation to GP-2250 for the treatment of all forms of pancreatic cancer.